Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients.
EGFR activating mutations
EGFR tyrosine kinase inhibitors
non-small-cell lung cancer
real-world practice
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
26
08
2020
revised:
28
09
2020
accepted:
01
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
19
8
2021
Statut:
ppublish
Résumé
First-generation or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are commonly used in In this retrospective study, real-world data of all patients who started first-line EGFR TKIs between 2012 and 2016 in Poland were analysed. The main endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were an objective response rate and toxicity. A total of 620 treatment-naive This study represents the largest RWE of first-line TKI therapy in a European country with longer survival of patients receiving second-generation TKI. We confirmed in everyday practice the role of toxicity as a marker of clinical benefit.
Sections du résumé
BACKGROUND
First-generation or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are commonly used in
PATIENTS AND METHODS
In this retrospective study, real-world data of all patients who started first-line EGFR TKIs between 2012 and 2016 in Poland were analysed. The main endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were an objective response rate and toxicity.
RESULTS
A total of 620 treatment-naive
CONCLUSION
This study represents the largest RWE of first-line TKI therapy in a European country with longer survival of patients receiving second-generation TKI. We confirmed in everyday practice the role of toxicity as a marker of clinical benefit.
Identifiants
pubmed: 33148621
pii: S2059-7029(20)32755-1
doi: 10.1136/esmoopen-2020-001011
pmc: PMC7640619
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Erlotinib Hydrochloride
DA87705X9K
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e001011Informations de copyright
© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.
Déclaration de conflit d'intérêts
Competing interests: AP reports personal fees and non-financial support from Roche, personal fees and non-financial support from Bristol Myers Squibb, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Boehringer Ingelheim, personal fees from MSD, personal fees and non-financial support from Astra Zeneca, personal fees from Takeda, outside the submitted work; DK reports and Advisory Board and Consultancy: Boehringer-Ingelheim, Roche, Astra Zeneca, Bristol-Myers Squibb, MSD, Amgen, Pfizer, Takeda, Merck, Novartis. RD reports personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Roche, personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Pfizer, personal fees from Celon Pharma, personal fees from Boehringer-Ingelheim, personal fees from FoundationMedicine, personal fees from Takeda, outside the submitted work.